Cabazitaxel
A taxane chemotherapy agent used to treat metastatic castration-resistant prostate cancer in patients who have previously received docetaxel-based treatment. It stabilizes microtubules to prevent cancer cells from dividing and is notable for activity in tumors that have become resistant to docetaxel. Severe neutropenia is its most serious side effect.
分子量
835.9000 g/mol
LogP
2.70
TPSA
202.00 Ų
リピンスキーの五則
不適合
治療領域
作用機序
Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.
2D構造
Cite this structure
Embed this structure
SMILES
CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
InChI
InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
Molecular Formula
C45H57NO14
HBD / HBA
3 / 14
回転可能結合数
15
重原子数
60
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
A taxane chemotherapy agent used to treat metastatic castration-resistant prostate cancer in patients who have previously received docetaxel-based treatment. It stabilizes microtubules to prevent cancer cells from dividing and is notable for activity in tumors that have become resistant to docetaxel. Severe neutropenia is its most serious side effect.
Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.
Yes, Cabazitaxel is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201748. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9854073. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cabazitaxel"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cabazitaxel/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cabazitaxel/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cabazitaxel/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cabazitaxel"></drugfyi-drug>